A Phase 1, Open Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine

Trial Profile

A Phase 1, Open Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2016

At a glance

  • Drugs Sumatriptan (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors NuPathe
  • Most Recent Events

    • 16 Feb 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 24 Sep 2013 New trial record
    • 23 Sep 2013 Dosing has been initiated, according to a NuPathe media release. Results of this study are expected in July 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top